Patients at high risk for cardiovascular disease or who had established cardiovascular disease had higher risk for a-fib with fish oil supplements
WEDNESDAY, May 19, 2021 (HealthDay News) — Fish oil supplements are associated with a significantly greater risk for atrial fibrillation (AF) in patients at elevated cardiovascular risk, according to a research letter published online April 28 in the European Heart Journal: Cardiovascular Pharmacotherapy.
Marco Lombardi, M.D., from the Catholic University of the Sacred Heart in Rome, and colleagues conducted a systematic literature review to identify randomized controlled trials evaluating omega-3 fatty acid supplementation on cardiovascular outcomes among participants with elevated triglycerides and either at high risk for cardiovascular disease or with established cardiovascular disease.
Based on five included studies (50,277 patients), the researchers found that omega-3 fatty acid supplementation is associated with an increased risk for incident AF versus placebo (incident rate ratio, 1.37). The VITAL rhythm trial was included in a sensitivity analysis, with results confirming a higher risk for AF in the group receiving supplementation versus placebo (incident rate ratio, 1.29). Follow-up ranged from two to 7.4 years, and the dose of fish oils varied from 0.84 g to 4 g per day.
“Although one clinical trial indicated beneficial cardiovascular effects of supplementation, the risk for atrial fibrillation should be considered when such agents are prescribed or purchased over the counter, especially in individuals susceptible to developing the heart rhythm disorder,” a coauthor said in a statement.
One author disclosed financial ties to the medical technology industry.
Iron Supplementation Likely to Reduce Iron-Deficiency Anemia in Children
Vitamin C Supplements in Pregnancy May Boost Infant Emotional Well-Being
Cannabis Legalization Linked to More Heart-Related Hospitalizations
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
CDC: 1 in 10 U.S. Adults Reported GLP-1 Medication Use July to August 2025
β3 Agonists Do Not Cut Dementia Risk Versus Anticholinergics in OAB
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus